News
Johnson & Johnson, Pharma and Beating Profit
Digest more
Analysts expect Johnson & Johnson to report an earnings per share (EPS) of $2.67. Johnson & Johnson bulls will hope to hear ...
Zacks Investment Research on MSN9d
JNJ vs. Pfizer: Which Pharma Giant is the Better Investment Now?Johnson & Johnson JNJ and Pfizer PFE rank among the world’s largest pharmaceutical companies, each with broad and diversified ...
Pfizer and Johnson & Johnson are two healthcare giants. Both have a solid earnings growth outlook, but they differ in terms of valuation, as well as in the dividend yields they offer right here.
The health sector is witnessing notable developments. Bristol Myers and Pfizer are offering Eliquis at a discounted rate.
Johnson & Johnson sought help from its three rival Covid-19 vaccine makers to look into reports of blood clots, but Pfizer and Moderna both declined, the Wall Street Journal reported on Friday ...
Johnson & Johnson expects to make $2.5 billion in revenue from its COVID-19 vaccine in 2021. That's a drop in the bucket for the mammoth business, which generated more than $80 billion in revenue ...
Some consumers have been wary of the Johnson & Johnson vaccine because its overall efficacy in clinical trials was 66% compared with about 95% for the Moderna and Pfizer vaccines.
The Pfizer vaccine is the first to receive FDA approval, while the Moderna and Johnson & Johnson vaccines are available under an emergency use authorization. For children ages 12 to 15 , ...
While the Pfizer and Moderna shots have a lot in common, the new Johnson & Johnson vaccine has some notable differences. A fourth COVID-19 inoculation, the AstraZeneca vaccine, may also soon be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback